News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Lilly and BioArctic team on brain-targeting drug delivery
Eli Lilly and BioArctic announced a research collaboration pairing a Lilly compound with BioArctic's BrainTransporter technology. The deal targets CNS disorders where blood-brain barrier penetration is the bottleneck.
Sanofi wins EU approval for first MS drug targeting disability without relapses
Cenrifki (tolebrutinib) becomes the first EU-authorised medicine designed to slow disability progression in secondary progressive MS without recent relapses. The approval follows phase 3 HERCULES trial data.
Pierre Fabre Wins EU Approval for First BRAF-Targeted Colorectal Cancer Drug
European Commission approves Braftovi combination therapy for BRAFV600E-mutant metastatic colorectal cancer. Phase 3 data show median progression-free survival of 12.8 months versus 7.1 months for chemotherapy alone.
AbbVie Pays $10.9B for Apogee to Lock Down Anti-IL-13 Pipeline
AbbVie will acquire Apogee Therapeutics for $10.9 billion, gaining zumilokibart, an injectable anti-IL-13 therapy designed for quarterly or biannual dosing in atopic dermatitis, asthma, and eosinophilic oesophagitis.
Lilly and BioArctic partner on blood-brain barrier tech for neurodegeneration
Eli Lilly partners with Swedish biotech BioArctic on a neurodegenerative therapy using BrainTransporter platform technology. BioArctic receives $30M upfront with potential $770M in milestones.
US opens trade probe into German drug price controls
The USTR triggered a Section 301 investigation into Germany's pharmaceutical pricing reforms, citing persistent underpayment for US medicines. Hearings set for September 2026—here's why the EU is watching closely.
Big Pharma stops poaching talent, starts pooling hiring instead
As onshoring reshapes US drug manufacturing, competitors are sharing recruitment plans through state forums rather than fighting for the same workers. Here's how North Carolina and Oregon are doing it.
Genprex Patents Gene Therapy Combo for Lung Cancer in Canada
Genprex secured Canadian patent protection for Reqorsa combined with PD-1/PD-L1 antibodies. The therapy is in Phase I/II trials pairing it with Genentech's Tecentriq for small cell lung cancer.
Intellia's CRISPR therapy hits secondary endpoints, stock surges 76% in six months
Intellia's lonvo-z met three key secondary endpoints in Phase III HAE trials, with 62% of patients attack-free for six months. The company expects FDA approval by mid-2027.
AbbVie Buys Apogee for $10.9B to Challenge Dupixent in Atopic Dermatitis
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, betting on zumilokibart, an IL-13 inhibitor dosed once every three to six months. The drug enters Phase III trials this year as a potential rival to Sanofi and Regeneron's $18 billion Dupixent.
AI Finds Antibiotic Candidates Hidden Inside Prion Proteins
University of Pennsylvania researchers used deep learning to scan prion proteins and discovered over 1,000 antimicrobial peptide candidates. Two showed efficacy matching polymyxin B in mouse infection models.
641 Schizophrenia Genes Found Via Long-Range Gene Networks
A new gene-network model identifies 641 previously unknown schizophrenia-linked genes by capturing how distant genetic variants regulate expression. Here's what the framework reveals about psychiatric disease.